262 related articles for article (PubMed ID: 20029466)
1. Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
Sidhom I; Shaaban K; Soliman S; Ezzat S; El-Anwar W; Hamdy N; Yassin D; Salem S; Hassanein H; Mansour MT
J Egypt Natl Canc Inst; 2008 Jun; 20(2):111-20. PubMed ID: 20029466
[TBL] [Abstract][Full Text] [Related]
2. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
3. [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia].
Chen LJ; Li JY; Wu YJ; Yang H; Qian SX; Wu HX; Lu H; Xu W; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):692-5. PubMed ID: 17708784
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.
Hann IM; Richards SM; Eden OB; Hill FG
Leukemia; 1998 Aug; 12(8):1249-55. PubMed ID: 9697880
[TBL] [Abstract][Full Text] [Related]
5. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotyping parameters as prognostic factors in T-acute leukemia patients.
Babusikova O; Stevulova L; Fajtova M
Neoplasma; 2009; 56(6):508-13. PubMed ID: 19728759
[TBL] [Abstract][Full Text] [Related]
10. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India.
Sharma M; Sachdeva MU; Varma N; Varma S; Marwaha RK
J Cancer Res Ther; 2016; 12(2):620-6. PubMed ID: 27461621
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
12. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients.
Liao H; Lai H; Chen J; Shuai X; Zhang X; Yang Y; Lyu M; Zheng Q
Cancer Med; 2023 Apr; 12(8):9615-9626. PubMed ID: 36951610
[TBL] [Abstract][Full Text] [Related]
14. [Characteristics of T-cell lineage immunophenotype in 95 patients with acute lymphoid leukemia].
Yuan TT; Liu YR; Chang Y; Hao L; Wang YZ; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1134-40. PubMed ID: 22040958
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Fuhrmann S; Schabath R; Möricke A; Zimmermann M; Kunz JB; Kulozik AE; Ludwig WD; Schrappe M; Karawajew L; Ratei R
Br J Haematol; 2018 Oct; 183(1):96-103. PubMed ID: 30028023
[TBL] [Abstract][Full Text] [Related]
17. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
18. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
20. CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis.
Garg N; Gupta R; Kotru M
Asian Pac J Cancer Prev; 2021 Mar; 22(3):919-925. PubMed ID: 33773558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
